Vor Biopharma

Founded 2015 · Biotech · Public

Engineered hematopoietic stem cells for transplantation and cancer therapy

Claim this profile

Follows are private to you and power your alerts

Updated · vorbiopharma.com

Sector
Biotech
Founded
2015
Latest Form D
$110M, Jul 2020
Total capital
$110M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$110M
1 Form D · last Jul 2020
76 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
23 pending · first 2025
Rank in peer group#481 of 1449

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $110M1st Form D$110M
2020FEDERAL ↑EQUITY ↓Cumulative $110M1st Form D$110M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$110M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Amy MendelExecutive OfficerNamed in SEC Form D filings
  • Joshua ResnickDirectorNamed in SEC Form D filings
  • Kush ParmarDirectorNamed in SEC Form D filings
  • Nathan JorgensenExecutive OfficerNamed in SEC Form D filings
  • Robert AngExecutive Officer, DirectorNamed in SEC Form D filings
  • Sven LundbergDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 24
  • PendingCompositions And Methods For EMR2 ModificationUSPTOApplication 18707965
  • PendingANTI-CD45-IGN Antibody Drug Conjugates And Uses ThereofUSPTOApplication 19085767
  • PendingMethods For Treating Autoimmune DiseasesUSPTOApplication 19312214
Show all 24 patent records
  • Compositions And Methods For EMR2 ModificationJun 11, 2026 · Application 18707965Pending
  • ANTI-CD45-IGN Antibody Drug Conjugates And Uses ThereofApr 16, 2026 · Application 19085767Pending
  • Methods For Treating Autoimmune DiseasesMar 12, 2026 · Application 19312214Pending
  • Therapeutic Methods Using Antibody Drug Conjugates (adcs)Jan 15, 2026 · Application 19067310Pending
  • Compositions And Methods For Artificial Protospacer Adjacent Motif (pam) GenerationJan 8, 2026 · Application 18881462Pending
  • Compositions And Methods For Mediating Epitope EngineeringSep 25, 2025 · Application 18853868Pending
  • Compositions And Methods For Homology-directed Repair Gene ModificationJun 5, 2025 · Application 18840740Pending
  • Genotyping Cells Using Single-cell Dna Sequencing DataMay 1, 2025 · Application 18920753Pending
  • Compositions And Methods For Gene ModificationApr 17, 2025 · Application 18293882Pending
  • Chimeric Antigen Receptors For Treatment Of CancerMar 13, 2025 · Application 18292499Pending
  • ANTI-CD45 Antibodies And Conjugates ThereofJan 28, 2025 · US 12,209,135Granted
  • Fusion Polypeptides For Genetic Editing And Methods Of Use ThereofDec 19, 2024 · Application 18695616Pending
  • Compositions And Methods For The Depletion Of CellsDec 12, 2024 · Application 18605123Pending
  • Compositions And Methods For Multiplex Base Editing In Hematopoietic CellsDec 12, 2024 · Application 18691720Pending
  • Inhibitor Oligonucleotides And Methods Of Use ThereofNov 21, 2024 · Application 18576181Pending
  • Nfat-responsive Reporter Systems For Assessing Chimeric Antigen Receptor Activation And Methods Of Making And Using The SameOct 24, 2024 · Application 18292590Pending
  • Photocleavable Guide Rnas And Methods Of Use ThereofJun 20, 2024 · Application 18285765Pending
  • Methods For Treating Hematopoietic MalignancyApplication 63597494Pending
  • Genotyping Cells Using Single-cell Dna Sequencing DataApplication 63592539Pending
  • Methods And Compositions For Gene Modification And EnrichmentApplication PCTUS2023075647Pending
  • Anti-CD45 Antibody-Drug Conjugate Pharmaceutical CompositionsApplication 63584107Pending
  • Compositions Comprising Genetically Engineered Hematopoietic Stem Cells And Methods Of Use ThereofApplication 63645618Pending
  • ANTI-CD45-IGN Antibody Drug Conjugates And Uses ThereofApplication PCTUS2023074713Pending
  • Methods For Treating Hematopoietic MalignancyApplication PCTUS2024015272Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .